{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:19Z","timestamp":1783401319268,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08237-1","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:28:17Z","timestamp":1781713697000},"page":"4609-4614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-9105","authenticated-orcid":false,"given":"Richard H.","family":"Woods","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"1","key":"8237_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00281-025-01064-7","volume":"47","author":"C Moltrasio","year":"2025","unstructured":"Moltrasio C, Romagnuolo M, Tavoletti G, Maronese CA, Marzano AV (2025) Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment. Semin Immunopathol 47(1):38. https:\/\/doi.org\/10.1007\/s00281-025-01064-7","journal-title":"Semin Immunopathol"},{"issue":"1","key":"8237_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","volume":"19","author":"JY Wang","year":"2018","unstructured":"Wang JY, French LE, Shear NH, Amiri A, Alavi A (2018) Drug-induced pyoderma gangrenosum: a review. Am J Clin Dermatol 19(1):67\u201377. https:\/\/doi.org\/10.1007\/s40257-017-0308-7","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"8237_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/01.ASW.0000820252.96869.8e","volume":"35","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Mufti A, Maliyar K, Sachdeva M, Yeung J (2022) Onset of pyoderma gangrenosum in patients on biologic therapies: a systematic review. Adv Skin Wound Care 35(8):454\u2013460. https:\/\/doi.org\/10.1097\/01.ASW.0000820252.96869.8e","journal-title":"Adv Skin Wound Care"},{"issue":"1","key":"8237_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00403-024-03689-4","volume":"317","author":"A Wanzenberg","year":"2025","unstructured":"Wanzenberg A, Keshock E, Sami N (2025) Anti-IL 17 biologics and pyoderma gangrenosum \u2013 therapeutic or causal? Arch Dermatol Res 317(1):235. https:\/\/doi.org\/10.1007\/s00403-024-03689-4","journal-title":"Arch Dermatol Res"},{"key":"8237_CR5","unstructured":"U.S. Food and Drug Administration (n.d.) FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files.\u00a0https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html.\u00a0Accessed 6 Oct 2025"},{"issue":"10","key":"8237_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/phar.2725","volume":"42","author":"RH Woods","year":"2022","unstructured":"Woods RH (2022) Alopecia signals associated with calcitonin gene\u2010related peptide inhibitors in the treatment or prophylaxis of migraine: a pharmacovigilance study. Pharmacother 42(10):758\u2013767. https:\/\/doi.org\/10.1002\/phar.2725","journal-title":"Pharmacother"},{"issue":"9","key":"8237_CR7","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/jid.2012.130","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan SM, Groves RW, Card TR, Gulliford MC (2012) Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 132(9):2166\u20132170. https:\/\/doi.org\/10.1038\/jid.2012.130","journal-title":"J Invest Dermatol"},{"key":"8237_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijscr.2018.02.026","volume":"44","author":"R Almukhtar","year":"2018","unstructured":"Almukhtar R, Armenta AM, Martin J et al (2018) Delayed diagnosis of post-surgical pyoderma gangrenosum: a multicenter case series and review of literature. Int J Surg Case Rep 44:152\u2013156. https:\/\/doi.org\/10.1016\/j.ijscr.2018.02.026","journal-title":"Int J Surg Case Rep"},{"issue":"37","key":"8237_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039634","volume":"103","author":"R Su","year":"2024","unstructured":"Su R, Tan Y, Peng S (2024) Clinical characteristics of pyoderma gangrenosum: case series and literature review. Medicine (Baltimore) 103(37):e39634. https:\/\/doi.org\/10.1097\/MD.0000000000039634","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"8237_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00403-025-03920-w","volume":"317","author":"T Tobey","year":"2025","unstructured":"Tobey T, Ortega-Loayza AG, Choe SI et al (2025) Pyoderma gangrenosum refined elements for core item selection and evaluation (PRECISE-PG): a study protocol for reaching consensus on core outcome domain items in clinical trials of pyoderma gangrenosum. Arch Dermatol Res 317(1):449. https:\/\/doi.org\/10.1007\/s00403-025-03920-w","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"8237_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.det.2023.12.002","volume":"42","author":"MG Tan","year":"2024","unstructured":"Tan MG, Tolkachjov SN (2024) Treatment of pyoderma gangrenosum. Dermatol Clin 42(2):183\u2013192. https:\/\/doi.org\/10.1016\/j.det.2023.12.002","journal-title":"Dermatol Clin"},{"key":"8237_CR12","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2380","author":"M Akahoshi-Ikeda","year":"2014","unstructured":"Akahoshi-Ikeda M, Yoshizawa S, Motoshita J, Furue M, Takeuchi S (2014) A case of pyoderma gangrenosum in a patient with rheumatoid arthritis treated with abatacept. Acta Derm Venereol. https:\/\/doi.org\/10.2340\/00015555-2380","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"8237_CR13","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1111\/bcp.14756","volume":"87","author":"F Borgia","year":"2021","unstructured":"Borgia F, Sutera D, Spagnolo A et al (2021) Onset of pyoderma gangrenosum after tocilizumab therapy for Takayasu arteritis: a new undescribed paradoxical reaction. Br J Clin Pharmacol 87(8):3378\u20133379. https:\/\/doi.org\/10.1111\/bcp.14756","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"8237_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ced.15183","volume":"47","author":"A Orita","year":"2022","unstructured":"Orita A, Hoshina D, Hirosaki K (2022) Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol 47(7):1372\u20131374. https:\/\/doi.org\/10.1111\/ced.15183","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"8237_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ced\/llac117","volume":"48","author":"IF Aromolo","year":"2023","unstructured":"Aromolo IF, Maronese CA, Moltrasio C et al (2023) Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab. Clin Exp Dermatol 48(3):293\u2013295. https:\/\/doi.org\/10.1093\/ced\/llac117","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"8237_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2021.12.028","volume":"87","author":"D Croitoru","year":"2022","unstructured":"Croitoru D, Nathanielsz N, Seigel K et al (2022) Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: a systematic review. J Am Acad Dermatol 87(3):655\u2013656. https:\/\/doi.org\/10.1016\/j.jaad.2021.12.028","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"8237_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","volume":"6","author":"AJ Petty","year":"2020","unstructured":"Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL (2020) Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep 6(8):731\u2013733. https:\/\/doi.org\/10.1016\/j.jdcr.2020.06.011","journal-title":"JAAD Case Rep"},{"key":"8237_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14611","author":"K Jin","year":"2019","unstructured":"Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D (2019) Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. https:\/\/doi.org\/10.1111\/1346-8138.14611","journal-title":"J Dermatol"},{"key":"8237_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13161","author":"U Wollina","year":"2020","unstructured":"Wollina U, Sch\u00f6nlebe J, F\u00fcrll C (2020) Pyoderma gangrenosum induced by secukinumab\u2014a late paradoxical drug reaction. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.13161","journal-title":"Dermatol Ther"},{"issue":"1","key":"8237_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00296-017-3861-8","volume":"38","author":"A Skalkou","year":"2018","unstructured":"Skalkou A, Manoli SM, Sachinidis A et al (2018) Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int 38(1):161\u2013167. https:\/\/doi.org\/10.1007\/s00296-017-3861-8","journal-title":"Rheumatol Int"},{"key":"8237_CR21","doi-asserted-by":"publisher","first-page":"1581996","DOI":"10.3389\/fimmu.2025.1581996","volume":"16","author":"W Xin","year":"2025","unstructured":"Xin W, Gu L, Du F, Li T, Ye S (2025) Case report: Spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy. Front Immunol 16:1581996. https:\/\/doi.org\/10.3389\/fimmu.2025.1581996","journal-title":"Front Immunol"},{"issue":"4","key":"8237_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40801-022-00322-6","volume":"9","author":"JB Hillen","year":"2022","unstructured":"Hillen JB, Stanford T, Ward M, Roughead EE, Kalisch\u202fEllett L, Pratt N (2022) Rituximab and pyoderma gangrenosum: an investigation of disproportionality using a systems biology-informed approach in the FAERS Database. Drugs Real World Outcomes 9(4):639\u2013647. https:\/\/doi.org\/10.1007\/s40801-022-00322-6","journal-title":"Drugs Real World Outcomes"},{"issue":"3","key":"8237_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","volume":"14","author":"R Sun","year":"2024","unstructured":"Sun R, Bustamante M, Gurusamy VK et al (2024) Safety of secukinumab from 1 million patient-years of exposure: experience from post-marketing setting and clinical trials. Dermatol Ther 14(3):729\u2013743. https:\/\/doi.org\/10.1007\/s13555-024-01122-2","journal-title":"Dermatol Ther"},{"issue":"6","key":"8237_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F et al (2018) Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis 28(6):533\u2013542. https:\/\/doi.org\/10.1016\/j.numecd.2018.02.014","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08237-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08237-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:26:51Z","timestamp":1783398411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08237-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8237"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08237-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RHW is an employee at a law firm that specializes in complex product liability litigation. The firm had no role in the concept, design or conduct of this study, and does not endorse the results or conclusions presented therein. The firm is not involved in litigation related to pyoderma gangrenosum and the medications analyzed in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}